# Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

> **NCT02173158** · PHASE3 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Familial Hypercholesterolemia - Homozygous

## Interventions

- **DRUG:** lomitapide

## Key facts

- **NCT ID:** NCT02173158
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-02
- **Primary completion:** 2015-04-03
- **Final completion:** 2015-12-17
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173158, "Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02173158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*